Gibson Dunn Advises Arrowhead Pharmaceuticals on Establishing “At the Market” Facility for Sale of up to $500 Million of Common Stock
Firm News | December 11, 2025
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on establishing an “at the market” facility for the sale of up to $500 million of its common stock. Arrowhead is a biotechnology company developing medicines that treat intractable diseases by silencing the genes that cause them.
Gibson Dunn regularly advises life sciences companies on capital markets transactions, including at-the-market offerings and equity financings.
The Gibson Dunn team included Ryan Murr, Melanie Neary, and Lauren Navarro.